Imaging Site Locator Registration Form

Please complete this form to authorize the addition of your imaging site's information.


Enrollment and participation is free, and does not impose any requirements on the manner in which the facility provides service to patients. Progenics Pharmaceuticals, Inc. (“Progenics”), a Lantheus company, does not recommend or endorse any site included in the PYLARIFY® Imaging Site Locator for any purpose. Participating sites on the PYLARIFY® Imaging Site Locator are listed based on the geographical search information entered. Progenics will host this information on Progenics websites, including but not limited to, and provide the information shared here to other vendors for the same purpose. Progenics retains the right to remove sites from the PYLARIFY® Imaging Site Locator, and agrees to remove the facility’s name upon written request.


PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.


  1. FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.